Smart science to improve lives™
Open search Basket 0 View basket
Pharma
banner representing sustainability for the earth and vaccines

Formulate the future: Unlocking sustainable ingredients for vaccines


We envision a future where everyone gets the vaccines they need. This reality relies on maintaining vaccine access and continuing to innovate in this realm. The responsibility is on us all to not only select sustainable ingredients, but to secure supply chains and sources that will not deplete in the future.

The vaccines of tomorrow

The vaccines of tomorrow revolve around, among other factors, sustainable supply chains and access to scalable commercial supplies that do not put undue pressure on the natural environment. It is our responsibility to future-proofed vaccines by focusing on longevity in our processes. With combined global efforts, we can enhance the global health infrastructure, leading us to develop vaccines with continually improving efficacy against more diseases and supporting our preparedness for future outbreaks.

Squalene and QS 21 are two highly-performing components of vaccine adjuvant systems that are currently used in lifesaving vaccines. However, they are both obtained from limited natural sources, leading to a search for more sustainable alternatives.

EXCLUSIVE WHITEPAPER: Vaccines for a more sustainable future

Download Croda Pharmas new whitepaper, Vaccines for a sustainable future
335.1 KB
squalene image with blue wash over image

Sustainably sourced Squalene

Introducing our sustainably sourced Squalene, produced using cutting-edge technology that centres on synthetic biology, our pharmaceutical-grade squalene has superior purity and carries the same squalene benefits as shark-derived squalene.

Register your interest for plant based squalene and qs21
Vaccine shown over map image

Sustainable saponins (2024)

As we look to become more nature positive, we’re proud to be able to offer our next-generation QS 21 and support global sustainability efforts. Our next-generation QS 21 is based on plant tissue culture, which makes the process more efficient and sustainably sourced.

Partnering for sustainable vaccines

Our partnerships with Amyris and BSI will expedite the commercial availability of sustainably sourced squalene and QS 21, and are two examples of putting our commitment, to be Climate, Land, People, and Nature Positive by 2030, into action. Our sustainably sourced solutions are comparable or go beyond their precursors, and offer consistent high purity.  For instance, our sugar-derived squalene uses fermentation to ensure consistently higher purity from a traceable and reliable source. The cutting-edge technology centres on synthetic biology to exceed monograph compliance and fulfil manufacturers' requirements. Meanwhile, our next-generation QS 21 uses a patented R&D platform based on plant tissue culture to offer a scalable, consistent, and more sustainable supply of QS 21.  

Contact us to continue your sustainable journey today!

Sustainably sourced squalene banner
The recent United Nations summit has stressed the urgency to strengthen global efforts to achieve the Sustainable Development Goals. This affects us all. In the vaccine industry, innovative technologies can enable truly sustainable solutions. We must act now to help develop the next generation of sustainable vaccines.
Our aseptic process ensures we can deliver sterile aluminium according to GMP EudraLex Volume 4. We are one of the only companies worldwide to operate at such premium standards. Our Quality Management System is continually improved through established metrics.

Exceptional standards in adjuvant manufacturing

Our aseptic process ensures we can deliver sterile aluminium according to GMP EudraLex Volume 4. We are one of the only companies worldwide to operate at such premium standards. Our Quality Management System is continually improved through established metrics.
As a key player in adjuvant development since 1939, our adjuvants have consistently been featured in countless peer-reviewed papers. Our leading R&D capabilities demonstrate our determination to advance drug delivery systems and novel vaccine adjuvants to tackle even more pathogens.

A history of supporting vaccines

As a key player in adjuvant development since 1939, our adjuvants have consistently been featured in countless peer-reviewed papers. Our leading R&D capabilities demonstrate our determination to advance drug delivery systems and novel vaccine adjuvants to tackle even more pathogens.
Developing and manufacturing vaccines is a costly challenge. Our team of experts are committed to helping you choose the right adjuvant for your needs. Save time and money by leveraging our decades worth of experience.

Dedicated to your vaccine success

Developing and manufacturing vaccines is a costly challenge. Our team of experts are committed to helping you choose the right adjuvant for your needs. Save time and money by leveraging our decades worth of experience.
Please provide your first name
Please provide your last name
E-mail is not valid
We need your consent
Please complete the recaptcha and resubmit the form.

Supporting Literature

Enter your contact details to receive supporting materials.

Addressing the challenges of vaccine formulation

Addressing the challenges of vaccine formulation brochure by Croda Pharma